Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study


ABSTRACT

Objective: The objective of this study was to compare international trends in pre-eclampsia rates and in overall pregnancy hypertension rates (including gestational hypertension, pre-eclampsia and eclampsia).

Design: Population data (from birth and/or hospital records) on all women giving birth were available from Australia (two states), Canada (Alberta), Denmark, Norway, Scotland, Sweden and the USA (Massachusetts) for a minimum of 6 years from 1997 to 2007. All countries used the 10th revision of the International Classification of Diseases, except Massachusetts which used the 9th revision. There were no major changes to the diagnostic criteria or methods of data collection in any country during the study period. Population characteristics as well as rates of pregnancy hypertension and pre-eclampsia were compared.

Results: Absolute rates varied across the populations as follows: pregnancy hypertension (3.6% to 9.1%), pre-eclampsia (1.4% to 4.0%) and early-onset pre-eclampsia (0.3% to 0.7%). Pregnancy hypertension and/or pre-eclampsia rates declined over time in most populations. This was unexpected given that factors associated with pregnancy hypertension such as pre-pregnancy obesity and maternal age are generally increasing. However, there was also a downward shift in gestational age with fewer pregnancies reaching term, the time when the pregnancy hypertension and pre-eclampsia are most likely to occur.

Conclusion: The rate of pregnancy hypertension and pre-eclampsia declined in northern Europe and Australia from 1997 to 2007, but increased in Massachusetts. The use of a different International Classification of Diseases coding version in Massachusetts may contribute to the difference in trend. Elective delivery prior to the due date is the most likely explanation for the decrease observed in Europe and Australia. Also, the use of interventions that reduce the risk of pregnancy hypertension and/or progression to pre-eclampsia (low-dose aspirin, calcium supplementation and early delivery for mild hypertension) may have contributed to the decline.

ARTICLE SUMMARY

Article focus

- The population prevalence of factors associated with increased and decreased risk of pregnancy hypertension and pre-eclampsia has changed over time, but the impact of these changes is unknown.
- International comparisons of absolute population rates of pregnancy hypertension and pre-eclampsia are hindered by different diagnostic criteria and methods of data collection.
- Comparing trends between countries overcomes the difficulties in comparing absolute rates.

Key message

- Pregnancy hypertension and/or pre-eclampsia rates declined over time in northern Europe and Australia, but not Massachusetts (USA).
- Declining hypertension rates were accompanied by a downward shift in gestational age with fewer pregnancies reaching term, the time when the pregnancy hypertension and pre-eclampsia are most likely to occur.

Strengths and limitations of this study

- Strengths include numerous validation studies indicating that the hypertensive disorders are reliably reported in the population data sets used for the study and the consistency of trends across most countries.
- Limitations include a different International Classification of Diseases coding version in Massachusetts and lack of available information on clinical interventions.

INTRODUCTION

Hypertension complicates up to 10% of all pregnancies and is associated with increased risk of adverse fetal, neonatal and maternal outcomes, including preterm birth, intrauterine growth restriction, perinatal death, acute renal or hepatic failure, antepartum...
haemorrhage, postpartum haemorrhage and maternal death. Pregnancy hypertension (also known as pregnancy-induced or pregnancy-associated hypertension) has its onset from 20 weeks of gestation and ranges from hypertension alone (gestational (non-proteinuric) hypertension) through proteinuria and multiorgan dysfunction (pre-eclampsia) to seizures (eclampsia). Pre-eclampsia may be superimposed on pre-existing chronic hypertension. Although pre-eclampsia represents the severe end of the spectrum, women with any form of pregnancy hypertension are at increased risk of adverse outcomes.

Risk factors for pregnancy hypertension and pre-eclampsia have been well documented. Factors that increase risk include nulliparity, older maternal age, multiple births, diabetes, chronic hypertension, obesity, previous pre-eclampsia, family history of pre-eclampsia, a new partner and/or ≥10 years since last pregnancy, renal disease, and the presence of antiphospholipid antibodies. Decreased risk of pregnancy hypertension and pre-eclampsia has been associated with placenta praevia, smoking (although smoking may only be protective in the non-obese), summer births, low-dose aspirin and calcium supplementation in high-risk women, treatment of gestational diabetes and use of antihypertensive medications. As the majority of cases of pregnancy hypertension and pre-eclampsia occur at term, increasing rates of early elective delivery may reduce their frequency. Trends in pregnancy hypertension and pre-eclampsia are the result of the effects of changes in all these factors.

Population rates of pregnancy hypertension (based on routinely collected data) vary substantially in high-income countries, ranging from 4% to 10%, including pre-eclampsia rates of 2% to 5%. As least part of this variation is likely due to underascertainment and/or misclassification of gestational hypertension and pre-eclampsia.

There are few recent reports of population trends in pregnancy hypertension. International comparisons of absolute population rates of pregnancy hypertension and pre-eclampsia have been considered ‘virtually impossible’ because of different diagnostic criteria and methods of data collection. However, comparing trends between countries overcomes the difficulties in comparing absolute rates. Provided that methods of reporting do not change from year to year, temporal variations in each country reflect true changes in that country’s rate of hypertension. The aim of this study was to determine and compare population-based trends in pregnancy hypertension and pre-eclampsia in high-income countries.

METHODS

We used population health data (record-linked birth and hospital data where available) to determine pregnancy hypertension and pre-eclampsia rates in Australia, Canada, Denmark, Norway, Scotland, Sweden and the USA. We pre-specified that (1) participating centres had to provide a minimum of 6 years of data in the period from 1997 to 2007, and (2) if coding of hypertension was based on the International Classification of Diseases (ICD), the same ICD version had to be used for the entire period. The latter stipulation was made because pre-eclampsia coding in ICD-9 and ICD-10 are not comparable.

Study populations and data sources

The study populations included all women who gave birth (both live births and stillbirths) during the study period. Eight collaborating centres provided population health data on a regional or national basis, including: Australia (the states of New South Wales (NSW) and Western Australia (WA)), Canada (province of Alberta); Denmark, Norway, Scotland, Sweden and the USA (state of Massachusetts). Table 1 provides the average population, number of births and information on the data sources in the eight study areas. The two Australian states account for approximately 43% of Australian births and together are referred to as ‘Australia’ in this paper. With the exception of the USA, all participating countries have universal health coverage for maternity care provided by midwives, general practitioners and obstetricians. Australia also has a parallel private healthcare system similar to that in the USA; about one-third of women seek private obstetric care.

Population health data were obtained from birth and/or hospital records in each study area. Birth data including information on maternal characteristics, pregnancy, labour, delivery and infant outcomes were collected by the attending midwife or doctor in a standard format. In Scotland, clinical coding staff within each hospital’s medical records department extracted the birth data from all available medical records. Hospital data included demographic, administrative and clinical data for all hospital discharges. Diagnoses and procedures for each admission were coded from the medical records according to the ICD. The number of diagnosis fields available in each medical record varied by study area, ranging from 6 to 25 (table 1). However, a consistent number of fields were used within each country over the time period of the study.

Record-linked birth and hospital data were utilised in Australia, Denmark and Massachusetts. In Denmark, the availability of a unique identifier allows unambiguous, deterministic linkage of records for each woman. In Australia and Massachusetts, unique identifiers are not available for record linkage. Consequently, probabilistic linkage methods were utilised. This involves a complex process of blocking and matching combinations of selected variables (such as name, date of birth, address and hospital) using record-linkage software. Probability weights are calculated, adjusted for incomplete and missing data, and used to determine correct matches. The validity of the probabilistic record linkage is extremely high, with less than 1% of records having an incorrect
<table>
<thead>
<tr>
<th>Maternal and pregnancy factors</th>
<th>Alberta, Canada</th>
<th>New South Wales, Australia</th>
<th>Western Australia, Australia</th>
<th>Denmark</th>
<th>Norway</th>
<th>Scotland</th>
<th>Sweden</th>
<th>Massachusetts, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>3.7 million</td>
<td>7.0 million</td>
<td>2.2 million</td>
<td>5.5 million</td>
<td>4.9 million</td>
<td>5.1 million</td>
<td>9.2 million</td>
<td>6.5 million</td>
</tr>
<tr>
<td>Births per annum</td>
<td>~42 000</td>
<td>~90 000</td>
<td>~25 000</td>
<td>~66 000</td>
<td>~60 000</td>
<td>~58 000</td>
<td>~100 000</td>
<td>~80 000</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>Live and stillbirths ≥20 weeks</td>
<td>Live and stillbirths ≥20 weeks or ≥400 g</td>
<td>Live and stillbirths ≥20 weeks or ≥400 g</td>
<td>≥22 weeks</td>
<td>≥22 weeks</td>
<td>≥22 weeks</td>
<td>≥22 weeks</td>
<td>≥20 weeks or ≥350 g</td>
</tr>
<tr>
<td>Source of population data</td>
<td>DAD (H), BRVS (B)</td>
<td>APDC (H), MDC (B)</td>
<td>HMDS (H), MNS (B)</td>
<td>DNRP, DMBR</td>
<td>MBRN</td>
<td>SMR02</td>
<td>SMBR</td>
<td>PELL</td>
</tr>
<tr>
<td>Linkage method</td>
<td>NA</td>
<td>H</td>
<td>Probabilistic B and/or H</td>
<td>Probabilistic H</td>
<td>Deterministic B</td>
<td>NA</td>
<td>NA</td>
<td>Probabilistic B and/or H</td>
</tr>
<tr>
<td>Source of hypertension data</td>
<td>25 (H)</td>
<td>11 (H)</td>
<td>21 (H)</td>
<td>20 (H)</td>
<td>Check-boxes and free text (B)</td>
<td>6 (B)</td>
<td>12 (B)</td>
<td>15 (H)</td>
</tr>
<tr>
<td>No of diagnosis fields</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-10</td>
<td>ICD-9</td>
</tr>
</tbody>
</table>

APDC, Admitted Patient Data Collection; B, Birth or obstetric data; BRVS, Birth Registry of Vital Statistics; DAD, Discharge Abstract Database; DMBR, Danish Medical Birth Registry; DNRP, Danish National Registry of Patients; H, Hospital data; HMDS, Hospital Morbidity Data System; ICD, International Classification of Diseases; MBRN, Medical Birth Registry of Norway; MDC, Midwives Data Collection; MNS, Midwives’ Notification System; NA, Not Applicable; PELL, Pregnancy to Early Life Longitudinal Data System; SMBR, Swedish Medical Birth Register; SMR02, Scottish Morbidity Record 2.
match.31–34 Once linked, and prior to release for analysis, records are stripped of identifying information.

**Primary outcomes: pregnancy hypertension and pre-eclampsia**

Population health data from each collaborating centre were used to estimate the overall incidence of any pregnancy hypertension (gestational hypertension, pre-eclampsia or eclampsia) and pre-eclampsia. During the study period, gestational hypertension was defined as the de novo onset of hypertension (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg) from 20 weeks’ gestation onwards and pre-eclampsia as the de novo onset of hypertension from 20 weeks’ gestation onwards accompanied by proteinuria.3

Information on maternal hypertension status was available from birth and/or hospital data (table 1). In the birth data, gestational hypertension, pre-eclampsia (in some cases by severity) and eclampsia data were generally collected as check-box fields and/or free text fields that were coded according to the ICD. In all hospital data, hypertension (as diagnosed by the attending clinician) was coded from the medical record according to the ICD. Because of expected variations in reporting and/or coding, we made an a priori decision that the optimal identification of pregnancy hypertension and pre-eclampsia would be based on local knowledge of reporting methods and validation studies of hypertension reporting. We aimed to achieve the best and most consistent reporting in each study area. Since our focus was on trends over time, our key concern was to ensure that data collection and reporting within each study area were consistent over the study period. It was clear that differences in the baseline rates between study areas would be unavoidable.

Validation studies focusing on reporting of hypertensive disorders of pregnancy in birth and hospital data from Europe, North America and Australia have shown remarkably consistent findings: pregnancy hypertension and pre-eclampsia are reliably and accurately reported in population health data; ascertainment is improved when hypertension is identified from more than one data source (birth and hospital records for the birth admission or birth and antenatal records)29 36; pre-eclampsia is generally better ascertained and more accurately reported than gestational hypertension;24 25 29; the broad category of ‘any pre-eclampsia’ is more reliably reported than subgroups stratified by severity;37 38; similarly the broad category of pregnancy hypertension is more accurately reported than the subgroups of pre-eclampsia and gestational hypertension, with the possible exception of countries where ascertainment of gestational hypertension is known to be low (including Denmark and Sweden).24 29 38 39

**Exposures**

The collaborating centres provided information on maternal and pregnancy characteristics of the study populations including age, parity, smoking at registration and/or during pregnancy, ethnicity, overweight/obesity (BMI ≥25.00 kg/m²), diabetes, chronic hypertension, multiple gestation, induction of labour, mode of delivery and gestational age. Preterm birth (<37 weeks gestation) was categorised as spontaneous or elective (planned/elective caesarean section before the onset of labour or induced labour). Gestational age was reported in completed weeks, based on the best available estimate from ultrasound dating and/or menstrual history. The most reliable source (birth and/or hospital data) was used to determine exposures.

**Approvals**

The Publication Board at the Medical Birth Registry of Norway and the Danish Registry Board approved the study. In NSW, the record linkage was approved by the NSW Population and Health Services Research Ethics Committee (2006-06-011). No other permissions were required for analysis and presentation of the data.

**Statistical analyses**

All analyses were based on women who delivered in each study location. We plotted secular trends in pregnancy hypertension and pre-eclampsia (per 100 deliveries per annum) for each study area based on available data over the study period. Temporal trends in numbers of pregnancy hypertension and pre-eclampsia events by study area were modelled using negative binomial regression. The covariance matrix was scaled by the deviance divided by the degrees of freedom and the additional variance component k estimated by maximum likelihood. Study year was fitted to the models, permitting estimation of yearly changes (with associated 95% CIs) in numbers of events relative to baseline. Model fit (p>0.2 in all models) was assessed using the Pearson $\chi^2$ goodness of fit statistic. Changes over time in population characteristics were analysed using the $\chi^2$ test for trend with the significance level set at p<0.01.

**RESULTS**

Data were available from the eight study areas for periods of 6 to 10 years between 1997 and 2007. The maternity populations ranged in size from an average of 25 000 per annum (pa) in Western Australia to 100 000 pa in Sweden (table 1). Although not measured from the same starting time or for the same duration, significant changes in the absolute number of women giving birth were observed in some areas, with increases in Alberta (by +26%), Sweden (+17%) and Australia (+7%), and declines in Scotland (−6%), Denmark (−4%) and Massachusetts (−4%). In Norway, deliveries declined from 1999 to 2002 (−6%) and then gradually returned to baseline in 2006.

Details of maternal and pregnancy characteristics and trends for each population are presented in table 2, highlighting some differences between study areas. The proportion of women delivering their first baby ranged from 40.7% in Norway to 45.2% in Scotland, and...
Table 2  Population characteristics by study area

<table>
<thead>
<tr>
<th>Maternal and pregnancy factors</th>
<th>Alberta Canada N=256137</th>
<th>NSW Australia N=732288</th>
<th>WA Australia N=149624</th>
<th>Denmark N=645993</th>
<th>Norway N=456353</th>
<th>Scotland N=531622</th>
<th>Sweden N=913779</th>
<th>Massachusetts USA N=762723</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study period</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>5.8</td>
<td>4.3*</td>
<td>4.6*</td>
<td>1.6*</td>
<td>2.4</td>
<td>8.3*</td>
<td>1.8</td>
<td>6.5</td>
</tr>
<tr>
<td>20–34</td>
<td>79.5</td>
<td>76.7*</td>
<td>75.2*</td>
<td>82.6</td>
<td>81.7</td>
<td>74.6*</td>
<td>80.1</td>
<td>71.5</td>
</tr>
<tr>
<td>≥35</td>
<td>14.7</td>
<td>19.0†</td>
<td>20.2†</td>
<td>15.8†</td>
<td>15.9†</td>
<td>17.1†</td>
<td>18.1†</td>
<td>22.0</td>
</tr>
<tr>
<td>Nullipara</td>
<td>44.2†</td>
<td>41.6†</td>
<td>41.6†</td>
<td>42.9†</td>
<td>40.7†</td>
<td>45.2†</td>
<td>43.9†</td>
<td>44.6</td>
</tr>
<tr>
<td>Multiple births</td>
<td>1.6†</td>
<td>1.6†</td>
<td>1.7</td>
<td>1.5†</td>
<td>1.9</td>
<td>1.5</td>
<td>1.5†</td>
<td>2.3</td>
</tr>
<tr>
<td>Diabetes (any)</td>
<td>4.0</td>
<td>5.4†</td>
<td>4.3</td>
<td>1.7†</td>
<td>1.5†</td>
<td>0.8</td>
<td>1.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>3.5</td>
<td>5.0†</td>
<td>3.8</td>
<td>1.3</td>
<td>0.8†</td>
<td>0.5</td>
<td>0.9</td>
<td>4.4</td>
</tr>
<tr>
<td>Pre-existing DM</td>
<td>0.5</td>
<td>0.4†</td>
<td>0.6</td>
<td>0.4</td>
<td>0.7†</td>
<td>0.4</td>
<td>0.4†</td>
<td>1.0</td>
</tr>
<tr>
<td>Chronic hypertension</td>
<td>0.4</td>
<td>1.2†</td>
<td>1.1</td>
<td>0.4†</td>
<td>0.6*</td>
<td>0.3</td>
<td>0.5†</td>
<td>1.6</td>
</tr>
<tr>
<td>Smoking</td>
<td>NA</td>
<td>17.4*</td>
<td>19.3*</td>
<td>20.6*</td>
<td>18.6*</td>
<td>24.8*</td>
<td>10.7†</td>
<td>12.3</td>
</tr>
<tr>
<td>Induction of labour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal vaginal</td>
<td>61.4*</td>
<td>64.8*</td>
<td>57.6</td>
<td>75.7*</td>
<td>77.3</td>
<td>65.3*</td>
<td>76.8*</td>
<td>66.5</td>
</tr>
<tr>
<td>Instrumental</td>
<td>13.0*</td>
<td>10.4*</td>
<td>12.4</td>
<td>7.2†</td>
<td>8.1†</td>
<td>12.5</td>
<td>7.5</td>
<td>6.1</td>
</tr>
<tr>
<td>Caesarean section</td>
<td>25.6†</td>
<td>24.7†</td>
<td>30.0†</td>
<td>17.1†</td>
<td>14.8†</td>
<td>22.2†</td>
<td>15.7†</td>
<td>27.4</td>
</tr>
<tr>
<td>Term births</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥40 weeks</td>
<td>40.1</td>
<td>49.6*</td>
<td>43.6*</td>
<td>54.1*</td>
<td>53.6*</td>
<td>54.4*</td>
<td>53.5*</td>
<td>53.5*</td>
</tr>
<tr>
<td>37–39 weeks</td>
<td>51.2</td>
<td>43.9†</td>
<td>48.8†</td>
<td>39.4†</td>
<td>40.0†</td>
<td>38.6†</td>
<td>40.8†</td>
<td>40.8†</td>
</tr>
<tr>
<td>Preterm births (all)</td>
<td>8.4</td>
<td>6.5†</td>
<td>7.6</td>
<td>6.5†</td>
<td>6.4</td>
<td>7.0</td>
<td>5.5</td>
<td>9.5</td>
</tr>
<tr>
<td>Elective—see below</td>
<td>2.5</td>
<td>2.5†</td>
<td>3.6†</td>
<td>1.3†</td>
<td>2.8</td>
<td>0.6§§</td>
<td>1.6</td>
<td>NA</td>
</tr>
<tr>
<td>Spontaneous</td>
<td>5.9</td>
<td>4.0</td>
<td>4.0</td>
<td>5.2</td>
<td>3.6</td>
<td>6.4</td>
<td>3.9†</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any pregnancy hypertension</td>
<td>6.0*</td>
<td>8.8*</td>
<td>9.1*</td>
<td>3.6</td>
<td>5.8</td>
<td>5.9*</td>
<td>3.9*</td>
<td>7.0†</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>1.4†</td>
<td>3.1*</td>
<td>2.9*</td>
<td>2.7*</td>
<td>4.0*</td>
<td>2.2*</td>
<td>2.9*</td>
<td>3.3†</td>
</tr>
<tr>
<td>Pre-eclampsia ≤34 weeks</td>
<td>0.7††</td>
<td>0.3</td>
<td>0.6</td>
<td>0.3</td>
<td>0.4</td>
<td>0.3</td>
<td>0.4</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Percentages may not total 100 because of missing data.
*Decreasing over the study period, \( \chi^2 \) for trend \( p<0.01 \).
†Increasing over the study period, \( \chi^2 \) for trend \( p<0.01 \).
†† Alberta—multiple birth data available for 98.5% of women.
‡‡ Denmark—smoking data available for 96% of women.
§§ Norway—daily smoking in the first trimester (available for 83% of women).
** Norway—daily smoking in the last trimester (available for 78% of women).
†††‡‡ Scotland—elective caesarean sections only.
increased in all populations. Multiple gestation rates were higher in Massachusetts, which also had the highest proportion of mothers aged ≥35 years. The Nordic countries (Denmark, Norway and Sweden) had lower rates of deliveries among teenagers, comparatively low rates of medical induction and operative deliveries (vaginal instrumental and caesarean deliveries), and lower rates of preterm birth. Maternal age increased over time in the Nordic countries, Australia and Scotland. Smoking declined, and inductions and caesarean sections increased in most study areas. Where data were available, there was a downward shift in gestational age at term with an increasing proportion of infants born at 37–39 weeks. This was accompanied by an increase in preterm births in NSW and Denmark. Information on the proportion of women who were overweight or obese was only available in Sweden (35.5%) and Denmark (32.1%). In Sweden, BMI information was available for 86% of women, and in Denmark data were available for 92% of women for 2004–2006, with no significant change in the rate of overweight or obesity during that period.

As anticipated, the reported rates of pregnancy hypertension (3.6% to 9.1%), pre-eclampsia (1.4% to 4.0%) and early onset pre-eclampsia (0.5% to 0.7%) varied between study areas. The contribution of pre-eclampsia to the pregnancy hypertension rate also varied from 23% in Alberta to 74% in Sweden (median=41%).

Figure 1 shows the trends in pregnancy hypertension rates for each study area. The average yearly rate decreased significantly during the study periods in four of the eight areas. In Scotland, pregnancy hypertension decreased by −6.2% pa (95% CI −5.2% to −7.3%), in WA by −4.8% pa (95% CI −4.1% to −5.5%), in NSW by −4.1% pa (95% CI −3.4% to −4.8%) and in Sweden by −0.6% pa (95% CI −0.1% to −1.1%). There was no significant change in the rate of pregnancy hypertension in Alberta (p=0.43), Denmark (p=0.23) or Norway (p=0.90), while in Massachusetts the rate increased significantly by 2.3% pa (95% CI 1.9% to 2.7%).

Trends in pre-eclampsia (figure 2) mirrored those of pregnancy hypertension in most study areas with significant decreases in NSW (−6.0% pa (95% CI −4.2% to −7.7%)), Scotland (−3.0% pa (95% CI −0.7% to −5.2%)), WA (−1.3% pa (95% CI −0.5% to −2.3%)) and Sweden (−1.2% pa (95% CI −0.6% to −1.8%)). A significant increase was observed in Massachusetts (2.4% pa (95% CI 1.5% to 3.3%)). Norway and Denmark experienced declines in pre-eclampsia rates (−2.5% pa (95% CI −1.4% to −3.5%) and −0.7% pa (95% CI −0.2% to −1.4%), respectively), despite the lack of significant reductions in pregnancy hypertension. In Alberta, the pre-eclampsia rate increased by 4.4% pa (95% CI 2.4% to 6.4%), albeit from a very low base rate of 1.1%. Where data were available, the trends in pregnancy hypertension and pre-eclampsia were similar when analyses were restricted to nulliparous women.

**DISCUSSION**

Most countries saw a decline in the rates of pregnancy hypertension and/or pre-eclampsia over time. This was an unexpected result, since factors thought to be positively associated with pregnancy hypertension such as pre-pregnancy overweight and obesity, diabetes, multiple births, and maternal age are generally recognised as increasing, while smoking during pregnancy (associated with reduced rates of pregnancy hypertension) has decreased. Trends in these factors have been proposed as possible explanations for the increase in pregnancy hypertension and pre-eclampsia rates reported for the entire USA from 1987 to 1998 (although the rates plateaued from 1999 to 2004). In contrast, a study from Western New York based on a perinatal database from 1999 to 2005 reported significant declines in both pregnancy hypertension and pre-eclampsia.

As expected, we observed a variation between study areas in baseline rates—more marked for pregnancy hypertension than for pre-eclampsia. However, for study areas with declining rates, the rates tended to converge over time. A significant part of the variation in baseline rates was likely related to differences in study population inclusion criteria and data-recording methods. Although the lower gestational age boundary varied by country (gestational age 20–22 weeks or birth weight 350–500 g for live births and 20–28 weeks for stillbirths), the impact was likely to be small as pregnancy hypertension

![Figure 1](http://bmjopen.bmj.com/) International trends in pregnancy hypertension. NSW, New South Wales; WA, Western Australia.

![Figure 2](http://bmjopen.bmj.com/) International trends in pre-eclampsia. NSW, New South Wales; WA, Western Australia.
and pre-eclampsia most frequently occur in the third trimester. Stillbirth, a complication of pre-eclampsia, is counted only from 28 weeks onwards in the Swedish data which may have reduced the country’s rates. However, the number of stillbirths <28 weeks was low (<2/1000 births), and the similar hypertension rates in Denmark (which included stillbirths in earlier weeks) argue against this as a significant explanation for observed differences in pregnancy hypertension rates. At the same time, validation studies from Denmark and Sweden indicated underenumeration of gestational hypertension compared with pre-eclampsia, which would explain the high ratio of pre-eclampsia to gestational hypertension in these countries.

Variability in the age, parity, chronic disease, smoking and multiple birth distributions will also influence the baseline rates of pregnancy hypertension and pre-eclampsia. Although data from Australia, the USA and Canada were from regional populations, these populations are likely to be more homogenous than the entire country populations and may be more similar to the European populations. Furthermore, the regional populations will have fewer climatic differences than experienced by entire countries like the USA, Canada and Australia.

The period of available data is another factor influencing the pregnancy profiles. For example, caesarean section rates tended to be lower in countries reporting for longer time periods; shorter, more recent periods have the highest rates. Although national and international guidelines defining pre-eclampsia and pregnancy hypertension were consistent during the study period, changes to Australian and New Zealand guidelines in 2008 may cause a greater divergence in baseline rates in the future. The inclusion of non-proteinuric hypertension with multiorgan disease in the clinical diagnosis of pre-eclampsia could increase the incidence of pre-eclampsia by up to 25% but should not affect the overall rate of pregnancy hypertension.

Finally, hospital data in all study areas, except Massachusetts, were coded using the 10th revision of the ICD. Unlike ICD-9, ICD-10 combines mild pre-eclampsia with gestational hypertension. While this should not affect the reported rate of pregnancy hypertension, it reduces the rate of pre-eclampsia in ICD-10 compared with ICD-9. The change in NSW from ICD-9 in 1997 to ICD-10 in 1998 coincided with a shift from an increasing to a decreasing trend in pregnancy hypertension, suggesting that the impact of the ICD version should not be disregarded. Furthermore, study areas with the highest rates of pregnancy hypertension (Australia and Massachusetts) have linked data and more diagnosis fields per record, characteristics shown to increase ascertainment in population data. Combinations of all these factors, as well as differences in the population of pregnant women, are likely contributors to differences in baseline rates between the study areas.

Although inconsistencies in diagnostic criteria, study populations, and temporal, geographic and demographic factors may explain differences in baseline rates, they do not explain the observed trends in pregnancy hypertension and pre-eclampsia. The year-to-year trends are influenced by the prevalence of risk factors in the study populations, prenatal care and therapeutic interventions. Many recognised risk factors for pregnancy hypertension and pre-eclampsia increased in all or some of our study populations during the study period, including nulliparity, advanced maternal age, diabetes, chronic hypertension and multiple pregnancy, while smoking rates (an apparent protective factor) declined everywhere. Diabetes, chronic hypertension and multiple pregnancy are associated with a two-to-three-fold increase in risk of pre-eclampsia, but occur infrequently. Small changes in the prevalence of these factors are unlikely to have a large impact on pregnancy hypertension rates in the population. While advanced maternal age and obesity are more common, the magnitude of risk is lower (less than double).

Although only a few countries could provide information on obesity in pregnant women, we assume that this is increasing in all participating countries, based on population trends. Nulliparity provides perhaps the most contrary and puzzling disparity in pre-eclampsia trends. Nulliparity is common (42–45%, increasing in most populations) and has an RR of pre-eclampsia estimated at 2.9 (95% CI 1.3 to 6.6). However, in our study, overall nulliparity rates did not correlate with the pre-eclampsia rates as expected. Instead, Scotland had both the lowest pre-eclampsia rates and the highest nulliparity rate, and Norway had the highest pre-eclampsia rates and the lowest nulliparity rate. Furthermore, the trends observed for all women were also observed among nullipara. Among multipara, pre-eclampsia in a prior pregnancy has been associated with a sevenfold increased risk in a subsequent pregnancy. Although women with pre-eclampsia are also less likely to have another pregnancy, this does not explain the lower overall risk of pre-eclampsia in parous women. Consequently, the impact of trends in parity on the population rates is complex and difficult to predict.

Changes in elective delivery (labour induction and caesarean section) are changing the distribution of gestational age at or near term. Increasing rates of early elective delivery before 40 weeks gestation have been reported internationally. Almost 90% of pregnancy hypertension and over 70% of pre-eclampsia events occur at term, but fewer pregnancies are reaching 40 weeks or beyond. Increasing rates of planned delivery of women with gestational hypertension could also explain why more study areas had decreases in pre-eclampsia rates. Reducing the median length of gestation by even a few days could mean that a substantial number of women now deliver before they become hypertensive. It is also possible that utilisation of
Interventions that reduce the risk of pregnancy hypertension and/or progression to pre-eclampsia (such as low-dose aspirin, calcium supplementation and possibly periconceptional multivitamin use in normal-weight women) are contributing to the decline in hypertension rates.\textsuperscript{15} 18 42 43

A strength of our study is the quality of information collected from very different health systems. While variation may occur in reporting, completeness and validity of data, there were no major changes in data collection or reporting methods during the study period. Validation studies of the reporting of hypertension in pregnancy have been conducted in Australia, Canada, Denmark, Norway, Sweden and the USA, with consistent findings about the reliability of each country’s ascertainment methods.\textsuperscript{24} 25 29 37–39 44 This consistency is important when examining the year-to-year variation.

In conclusion, we found declining rates of pregnancy hypertension and pre-eclampsia in northern Europe and Australia, a reassuring finding in the context of increasing maternal age, nulliparity and obesity. However, an increase in these rates was observed in Massachusetts. It is unclear whether the different ICD coding version used in the USA played a role in this finding. The role of elective delivery prior to the due date (especially late preterm and early term) in limiting the period of gestation during which the pregnancy hypertension and pre-eclampsia risks are greatest warrants further investigation.

Author affiliations:
\textsuperscript{1}Perinatal Research, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia
\textsuperscript{2}Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark
\textsuperscript{3}Information Services Division, NHS National Services, Edinburgh, UK
\textsuperscript{4}Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
\textsuperscript{5}Maternal and Child Health Department, Boston University School of Public Health, Boston, Massachusetts, USA
\textsuperscript{6}Medical Birth Registry of Norway, University of Bergen and the National Institute of Public Health, Bergen, Norway
\textsuperscript{7}Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia
\textsuperscript{8}Tommys Centre for Maternal and Fetal Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
\textsuperscript{9}Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
\textsuperscript{10}Department of Community Health Sciences, University of Calgary, Alberta, Canada
\textsuperscript{11}Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, UK

Acknowledgements Population health data were generously provided by the Alberta Discharge Abstract Database and Birth Registry of Vital Statistics, NSW Department of Health, WA Department of Health, the Danish National Registry of Patients and Medical Birth Registry, the Medical Birth Registry of Norway, Information Services Division of NHS National Services Scotland, the Swedish Medical Birth Register and a public–private partnership between the Boston University School of Public Health, and the Massachusetts Department of Public Health, through a public–private partnership with Boston University School of Public Health and the Centers for Disease Control and Prevention, USA. We thank the NSW Centre for Health Record Linkage and the WA Data Linkage System for record linkage. We are also indebted to S Hernandez-Diaz for introducing the Nordic members of the collaboration.

Funding
The research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. However, CLR was supported by a NHMRC Senior Research Fellowship (no 457078) and a McKerr Travelling Research Scholarship. JBF was supported by NHMRC Capacity Building funding (no 573122), and CJW was supported by the Edinburgh MRC Hub for Trials Methodology Research.

Competing interests None.

Ethics approval NSW Population and Health Services Research Ethics Committee.

Contributors CLR and JBF conceived the project and developed the idea in collaboration with JMM, JC, JEN, JN and CJW. All authors contributed to study design, CLR, JC, SC, MK, KMM, NN, HTS and RW were responsible for data acquisition, and CSA, SA, SC, MG, KKKM, AL, CM, RW and CJW contributed to the analysis of data. CLR and JBF initially drafted the manuscript, and all authors were involved in critical revision of the intellectual content. All authors approved the final manuscript.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

REFERENCES

### STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*

*Checklist for cohort, case-control, and cross-sectional studies (combined)*

<table>
<thead>
<tr>
<th>Section/Topic</th>
<th>Item #</th>
<th>Recommendation</th>
<th>Reported on page #</th>
</tr>
</thead>
</table>
| Title and abstract | 1 | *(a) Indicate the study’s design with a commonly used term in the title or the abstract*  
 *(b) Provide in the abstract an informative and balanced summary of what was done and what was found* | 1, 2              |
| Introduction  |        | | 4-5                                                             | 5                 |
| Methods       |        | | 6-7, 22, 24                                                        |                   |
| Study design  | 4      | Present key elements of study design early in the paper                                                                                                                                                    | 5-6               |
| Setting       | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection                                                                             | 6-7, 22, 24       |
| Participants  | 6      | *(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up*  
 *(Case-control study)—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls*  
 *(Cross-sectional study)—Give the eligibility criteria, and the sources and methods of selection of participants*  
 *(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed*  
 *(Case-control study—For matched studies, give matching criteria and the number of controls per case)* | 6-8, 22           |
| Variables     | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                                         | 7-8               |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7-8, 22           |
| Bias          | 9      | Describe any efforts to address potential sources of bias                                                                                                                                                    | 9                 |
| Study size    | 10     | Explain how the study size was arrived at                                                                                                                                                                 | NA (population data) |
| Quantitative variables | 11  | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why                                                                                     | 9                 |
| Statistical methods | 12  | *(a) Describe all statistical methods, including those used to control for confounding*  
 *(b) Describe any methods used to examine subgroups and interactions*  
 *(c) Explain how missing data were addressed*  
 *(d) Cohort study—If applicable, explain how loss to follow-up was addressed*  
 *(Case-control study—If applicable, explain how matching of cases and controls was addressed)* | 9, 24, NA (population data) |
### Results

| Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy  
| (e) Describe any sensitivity analyses  |
|---|---|
| Participants | 13* |  
| (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,  
confirmed eligible, included in the study, completing follow-up, and analysed  |
| (b) Give reasons for non-participation at each stage  |
| (c) Consider use of a flow diagram  |
| Descriptive data | 14* |  
| (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and  
potential confounders  |
| (b) Indicate number of participants with missing data for each variable of interest  |
| (c) Cohort study—Summarise follow-up time (eg, average and total amount)  |
| Outcome data | 15* |  
| (a) Report numbers of outcome events or summary measures over time  
| Case-control study—Report numbers in each exposure category, or summary measures of exposure  
| Cross-sectional study—Report numbers of outcome events or summary measures  |
| Main results | 16 |  
| (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95%  
confidence interval). Make clear which confounders were adjusted for and why they were included  |
| (b) Report category boundaries when continuous variables were categorized  |
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
| Figures 1 and 2  |
| Other analyses | 17 |  
| Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  |

### Discussion

| Key results | 18 | Summarise key results with reference to study objectives  |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction  
and magnitude of any potential bias  |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results  
from similar studies, and other relevant evidence  |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results  |

### Other information

| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on  
which the present article is based  |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.*

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.